Bosutinib

Treatment of Chronic Myeloid Leukemia

Bosutinib is used to treat Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML). This is a type of cancer that starts in the bone marrow and causes the body to produce too many abnormal white blood cells. The medication is used for patients in different stages of the disease and across various age groups.

Adult Indications

In adults, bosutinib is prescribed for Ph+ CML in the following situations:

• Newly diagnosed cases: It may be used as an initial treatment for patients in the chronic phase of the disease.
• Resistance or intolerance: It is used for patients in the chronic, accelerated, or blast phases of CML when other treatments have not worked or have caused side effects that the patient could not tolerate.

Pediatric Indications

Bosutinib is approved for use in children 1 year of age and older who have Ph+ CML in the chronic phase. This includes:

• Children who are newly diagnosed with the condition.
• Children who have previously tried other treatments that were either ineffective or caused intolerable side effects.

This medication belongs to a class of drugs known as kinase inhibitors, which work by blocking the action of the abnormal protein that signals cancer cells to multiply.

Mechanism of Action

Bosutinib is designed to treat certain types of chronic myeloid leukemia (CML). In many cases of CML, a genetic change creates an abnormal protein called Bcr-Abl. This protein acts as a signal that tells white blood cells to divide and grow much faster than they should, leading to a buildup of diseased cells.

Bosutinib works by identifying and blocking this Bcr-Abl protein. By interfering with this signaling pathway, the medication helps to:

• Stop or slow the production of abnormal white blood cells.
• Reduce the overall number of leukemia cells in the body.
• Allow the bone marrow to produce healthy blood cells again.

In addition to targeting Bcr-Abl, bosutinib also inhibits other proteins called Src-family kinases. These proteins are also involved in the growth and survival of cancer cells. By blocking multiple pathways at once, the drug provides a targeted approach to managing the disease.

Common Side Effects

Many people taking bosutinib experience mild to moderate side effects. These often include:

• Diarrhea, nausea, vomiting, or stomach pain
• Feeling tired or weak
• Fever or cough
• Rash or itchy skin
• Headache or dizziness
• Loss of appetite
• Joint, back, or muscle pain
• Swelling in the hands, feet, or ankles

Serious Side Effects

Some side effects can be serious and require immediate medical attention. Contact a doctor right away if you experience:

• Severe diarrhea: Frequent, watery stools that may lead to dehydration.
• Liver problems: Yellowing of the skin or eyes (jaundice), dark urine, or pain in the upper right side of the stomach.
• Low blood cell counts: Increased risk of infection (fever, chills), unusual bruising or bleeding, and feeling very tired or short of breath.
• Fluid retention: Sudden weight gain, swelling around the eyes, or shortness of breath.
• Heart or lung issues: Chest pain, irregular heartbeat, or a new or worsening cough.
• Kidney problems: Changes in how much or how often you urinate.
• Severe skin reactions: Redness, blistering, or peeling skin.

Gastrointestinal Toxicity

Severe diarrhea, nausea, vomiting, and abdominal pain can occur during treatment. These symptoms often appear early in the course of therapy and may require medical management or dose modifications.

Myelosuppression

Bosutinib can cause a significant decrease in blood cell counts, including platelets, red blood cells, and white blood cells. This condition, known as myelosuppression, increases the risk of bleeding and infection. Blood counts are typically monitored frequently during the first few months of treatment.

Liver Toxicity

Elevations in liver enzymes and bilirubin have been reported, which may indicate liver injury. Liver function tests are generally performed monthly for the first three months of treatment and then as clinically indicated. Patients with a history of liver problems may require closer monitoring or dose adjustments.

Fluid Retention

Fluid retention can lead to complications such as pleural effusion (fluid around the lungs), pericardial effusion (fluid around the heart), or pulmonary edema. Patients should be monitored for symptoms like sudden weight gain or shortness of breath.

Renal Toxicity

A decline in kidney function has been observed in some patients. Monitoring of renal function is recommended before starting treatment and periodically during therapy.

Embryo-Fetal Toxicity

Based on its mechanism of action, bosutinib can cause fetal harm when administered to pregnant individuals. Effective contraception should be used during treatment and for at least two weeks after the last dose.

Pregnancy

Bosutinib may cause fetal harm if taken during pregnancy. Research in animals has shown that the medication can lead to decreased fetal body weight and skeletal variations. Healthcare providers advise individuals who can become pregnant to use effective birth control during treatment and for at least two weeks after the last dose.

If you are pregnant or planning to become pregnant, discuss your options and the potential risks with your healthcare team. If you suspect you have become pregnant while taking this medication, contact your doctor right away.

Breastfeeding

It is currently unknown if bosutinib passes into human breast milk. Because of the potential for serious adverse reactions in a nursing child, it is recommended that you do not breastfeed while taking this medication and for at least two weeks after the final dose.

Available Forms

Bosutinib is available as an oral medication. It is produced in the following forms:

• Tablets: Film-coated tablets for oral use.
• Capsules: Oral capsules.

FDA Approval Status

Bosutinib was first approved by the U.S. Food and Drug Administration (FDA) in 2012. It is currently indicated for the treatment of:

• Adults with newly-diagnosed chronic phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML).
• Adults with chronic, accelerated, or blast phase Ph+ CML who are resistant or intolerant to prior therapy.
• Pediatric patients 1 year of age and older with newly-diagnosed chronic phase Ph+ CML or those who are resistant or intolerant to prior therapy.

Safety Monitoring and Communications

There are no boxed warnings or Risk Evaluation and Mitigation Strategies (REMS) currently required for bosutinib. However, the FDA has previously identified and monitored potential safety signals through the FDA Adverse Event Reporting System (FAERS), including risks such as interstitial lung disease.

Prescription Requirements

Bosutinib is a prescription medication, and its cost is primarily determined by the patient's health insurance plan and the specific dosage required for treatment. It is available in several strengths, including 100 mg, 400 mg, and 500 mg tablets, which can affect the overall price.

Insurance Coverage

Coverage for bosutinib varies between different insurance providers, including private plans and government-funded programs like Medicare. Patients may need to undergo a prior authorization process, where the insurance company reviews the medical necessity of the drug before approving coverage. The out-of-pocket expense often depends on whether the drug is placed on a specialty tier within the insurance formulary.

Accessing the Medication

Because bosutinib is used for specific medical conditions like chronic myelogenous leukemia, it may not be stocked at all local pharmacies. Patients often receive this medication through specialized pharmacy services that handle oncology treatments. For those concerned about the cost, healthcare providers or hospital financial counselors can often provide information on programs designed to help manage the expense of long-term treatment.